Date prepared: June 15, 2022<\/p>\n\n\n\n
Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering \u2013 current and periodical information<\/p>\n\n\n\n
Content of the report:<\/p>\n\n\n\n
As a supplement to current report No. 13\/2022 dated May 26, 2022 announcing the Ordinary General Meeting of Celon Pharma S.A. convened to take place on June 22, 2022 along with draft resolutions, the Management Board of Celon Pharma S.A. (“Company”) attaches hereto reports drawn up by the Supervisory Board, submitted to the Ordinary General Meeting of the Company:<\/p>\n\n\n\n
– Report of the Supervisory Board of Celon Pharma S.A. for the financial year 2021 taking into account requirements specified in the Best Practice for GPW Listed Companies 2021, the examination and approval of which constitute points 7 and 11 of the agenda for the Ordinary General Meeting,<\/p>\n\n\n\n
– Report on remuneration of Members of the Management Board and the Supervisory Board for the period 01.01.2021.-31.12.2021, for which an opinion is to be issued as point 14 of the agenda, together with the Report of the independent statutory auditor of the attestation services covering evaluation of this report.<\/p>\n","protected":false},"excerpt":{"rendered":"